Maas J W, Miller A L, Tekell J L, Funderburg L, Silva J A, True J, Velligan D, Berman N, Bowden C L
Department of Psychiatry, University of Texas Health Science Center at San Antonio 78284-7792, USA.
J Clin Psychopharmacol. 1995 Oct;15(5):361-4. doi: 10.1097/00004714-199510000-00009.
Because of the evidence for increased norepinephrine (NE) production in psychotic patients, we studied the effects of combining the alpha 2-adrenergic agonist clonidine with haloperidol for the treatment of schizophrenic psychosis. Twelve hospitalized schizophrenic patients were taken off their antipsychotic medication for 2 to 4 weeks before double-blind treatment with haloperidol (20 mg/day) combined with either clonidine or placebo. The group receiving clonidine was significantly more improved on the thought disorder subscale of the Brief Psychiatric Rating Scale (p = 0.02). The groups differed initially in the level of negative symptoms, but not controlling for this difference statistically by analysis of covariance did not change the finding with regard to the superiority of combining clonidine with haloperidol. We conclude that larger treatment trials of combining haloperidol with clonidine are warranted.
由于有证据表明精神病患者去甲肾上腺素(NE)分泌增加,我们研究了α2 - 肾上腺素能激动剂可乐定与氟哌啶醇联合用于治疗精神分裂症性精神病的效果。12名住院的精神分裂症患者在接受氟哌啶醇(20毫克/天)与可乐定或安慰剂的双盲治疗前,停用抗精神病药物2至4周。接受可乐定治疗的组在简明精神病评定量表的思维障碍分量表上改善更为显著(p = 0.02)。两组在阴性症状水平上最初存在差异,但通过协方差分析未对该差异进行统计学控制,这并未改变可乐定与氟哌啶醇联合使用具有优越性这一结果。我们得出结论,有必要进行更大规模的氟哌啶醇与可乐定联合治疗试验。